Is the polymorphism in the promoter region of CYP17 gene a risk factor for prostate cancer in Polish population?

Nowotwory

Volumn 53, Issue 5, 2003, Pages 521-525

  Gos, Monika ^a   Sadowska, Małgorzata ^a   Grzegrzółka, Marek ^b   Demkow, Tomasz ^a   Janik, Przemysław ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b Rlwy Admin Central Hospital   (Poland)

Author keywords

Androgen metabolism; CYP17; Cytochrome P450c17 ; Prostate cancer

Indexed keywords

AGAROSE; CYTOCHROME P450 17; ETHIDIUM BROMIDE; PROSTATE SPECIFIC ANTIGEN; SEX HORMONE; STEROID HORMONE;

AGE; AGED; ARTICLE; CANCER INCIDENCE; CANCER RISK; CARCINOGENESIS; CONTROLLED STUDY; DNA EXTRACTION; GENE AMPLIFICATION; GENETIC POLYMORPHISM; GENOTYPE; HORMONE SYNTHESIS; HUMAN; MALE; POLAND; PROMOTER REGION; PROSTATE CANCER;

EID: 0242665593     PISSN: 0029540X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Zatoński, WA, Tyczyński, JE. Epidemiologia nowotworów złośliwych w Polsce wpiȩtnastoleciu 1980-1994. Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie: Warszawa; 1997.
2. Kowalczyk B. Rak prostaty w Medicover online - 2000.
3. Lunn RM, Bell DA, Mohler JL et al. Prostate cancer risk and polymorphism in 17 hydroxylase /CYP17/ and steroid reductase /SRD5A2/. Carcinogenesis 1999; 20: 1727-31.
4. Mould RF. Prostate cancer incidence review with emphasis on publications from the Amercian Cancer Society & the International Agency for Research on Cancer. Nowotwory 2002; 52: 11-5.
5. Tyczyński JE, Wojciechowska U, Didkowska J et al.-Atlas umieralności na nowotwory złośliwe w Polsce w latach 1991-1995. Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie: Warszawa; 1998.
6. Nwosu N, Carpten J, Trent JM et al. Heterogenity of genetic alterations in prostate cancer: evidence of the complex nature of the disease. Hum Molec Genet 2001; 10: 2313-8.
7. Feigelson HS, Shames LS, Pike MC et al. Cytochrome P450c17α gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Res 1998; 58: 585-7.
8. Kristensen VN, Haraldsen EK, Anderson KB et al. CYP17 and breast cancer risk: the polymorphism in the 5′ flanking area of the gene does not influence binding to Sp-1. Cancer Res 1999; 59: 2825-8.
9. Wadelius M, Andersson AO, Johansson JE et al. Prostate cancer associated with CYP17 genotype. Pharmacogenetics 1999; 9: 635-9.
10. Chang B, Zheng SL, Isaacs SD et al. Linkage and association of /CYP17/ gene in hereditary and sporadic prostate cancer. Int J Cancer (Pred Oncol) 2001; 95: 354-9.
11. Habuchi T, Liqing Z, Suzuki T et al. Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect. Cancer Res 2000; 60: 5710-3.
12. Kittles RA, Panguluri RK, Chen W et al. /CYP17/ promoter variantl associated with prostate cancer aggressiveness in African American. Cancer Epidemiol Biomark Prev 2001; 10: 943-7.
13. Gsur A, Bemhofer G, Hinteregger S et al. A polymorphism in the CYP17 gene is associated with prostate cancer risk. Int J Cancer 2000; 87: 434-71.
14. Yamada Y, Watanabe M, Murata M wt al. Impact of genetic, polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5α-reductase type II (SRD5A2) genes on prostate cancer risk among the Japanese population. Int J Cancer 2001; 92: 683-6.
15. Allen NE, Forrest MS, Key TJ.-The association between polymorphisms in the CYP17 and 5α-reductase (SRD5A2) genes and serum androgen concentrations in men. Cancer Epidemiol Biomark Prev 2001; 10: 185-9.
16. Haiman CA, Stampfer MJ, Giovannucci E et al. The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer. Cancer Epidemiol Biomark Prev 2001; 10: 743-8.
17. Giovannucci E, Stampfer MJ, Krithivas K, Brown M, Dahl D, Brufsky A, Talcott J, Hennekens CH, Kantoff PW. - The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. PNAS 1997; 94: 3320-3.
18. Stanford JL, Just JJ, Gibbs M et al. Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Res 1997; 57: 1194-8.